This week we talk about new treatment approvals for acute migraine, dry eye disease and schizophrenia; a new indication for Xarelto; and the Centers for Disease Control and Prevention issue an interim guidance for physicians regarding electronic cigarette, or vaping, product use-associated lung injury, or 'EVALI'.

This week we talk about the FDA highlighting THC in the recent spate of vaping-related illnesses; Descovy's expanded approval; A new cream for acne; A treatment for the rare condition possibly behind the creation of vampire myths; and a new drug approval for the treatment of wet age-related macular degeneration.

This week: New Invokana approval; More ranitidine recalls lead CVS to suspend all sales; FDA has identifies 11 serious cybersecurity vulnerabilities that could affect medical devices and hospital networks; Entresto indication expanded; and COPD investigate treatment is rejected.

This week: A new tablet treatment for type 2 diabetes; Pancreatitis treatment gains Orphan Drug status; New approval for smallpox, monkeypox; An investigational treatment for Guillain-Barré Syndrome; and big changes at e-cigarette maker, Juul.

This week: FDA votes on possible peanut allergy treatment; New risks ID'd with some breast cancer drugs; a topical solution for common warts edges nearer; Nitrosamine impurity identified in acid suppressant; And news of another e-cigarette related fatality.

This week: New adjunct treatment for Parkinson disease; Pain med associated with hypoglycemia; New approval for active ankylosing spondylitis; Fast track designation for possible kidney disease therapy; and a possible treatment for degenerative disc disease.

This week: New draft guidelines for Lyme Disease management; First-in-class antibiotic to treat community-acquired bacterial pneumonia; Duchenne muscular dystrophy drug denied; Approval for a rheumatoid arthritis treatment; and the FDA make a decision on Hetlioz for jet lag disorder.

This week the team discuss the 'Cure All' treatments that contain bleach, news concerning a Parkinson disease treatment, a new approval for a tuberculosis treatment, differences between the US and Canada in prescription drug use, and a new point-of-care, sexually transmitted infection test.